Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?

Dengue is an increasingly important cause of morbidity and mortality in the tropics, but vaccine development has been impeded by a poor understanding of disease pathogenesis and, in particular, of immunologic enhancement. In a large case-control study of Vietnamese patients with dengue hemorrhagic fever (DHF), variation at the HLA-A locus was significantly associated with susceptibility to DHF (P=.02), and specific HLA-A susceptibility and resistance alleles were identified. HLA-A-specific epitopes were predicted from binding motifs, and ELISPOT analyses of patients with DHF revealed high frequencies of circulating CD8 T lymphocytes that recognized both serotype-specific and -cross-reactive dengue virus epitopes. Thus, strong CD8 T cell responses are induced by natural dengue virus infection, and HLA class I genetic variation is a risk factor for DHF. These genetic and immunologic data support both protective and pathogenic roles for dengue virus-specific CD8 T cell responses in severe disease. The potentially pathogenic role of serotype-cross-reactive CD8 T cells poses yet another obstacle to successful dengue vaccine development.

[1]  T. Monath,et al.  Dengue: the risk to developed and developing countries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Vaughn,et al.  Predominance of HLA-Restricted Cytotoxic T-Lymphocyte Responses to Serotype-Cross-Reactive Epitopes on Nonstructural Proteins following Natural Secondary Dengue Virus Infection , 1998, Journal of Virology.

[3]  M. Moffatt,et al.  P874 - Asthma and tumour necrosis factor polymorphism , 1996 .

[4]  R. Rico-Hesse,et al.  Dengue Virus Structural Differences That Correlate with Pathogenesis , 1999, Journal of Virology.

[5]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[6]  M. Kron,et al.  Threat of dengue haemorrhagic fever after yellow fever vaccination , 1997, The Lancet.

[7]  W. Cookson,et al.  Tumour necrosis factor haplotypes and asthma. , 1997, Human molecular genetics.

[8]  Y. Tan,et al.  Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. , 1996, Virology.

[9]  F. Ennis,et al.  Cytotoxic T lymphocytes in dengue virus infection. , 1994, Current topics in microbiology and immunology.

[10]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[11]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[12]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[13]  R. M. Scott,et al.  Histocompatibility antigens and dengue hemorrhagic fever. , 1981, American Journal of Tropical Medicine and Hygiene.

[14]  P. Basanta,et al.  Association of dengue hemorrhagic fever with the HLA system. , 1987, Haematologia.

[15]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.

[16]  M. Guzmán,et al.  Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. , 1990, The American journal of tropical medicine and hygiene.

[17]  M. Barnardo,et al.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[18]  A. McMichael,et al.  HLA and MHC: Genes, Molecules And Function , 1997, Nature Medicine.

[19]  N. Bhamarapravati,et al.  Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.

[20]  A. Nisalak,et al.  Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. , 1991, The Journal of clinical investigation.

[21]  S. Halstead,et al.  Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. , 1984, American journal of epidemiology.

[22]  D. Gubler,et al.  Dengue and dengue haemorrhagic fever , 1998, The Lancet.

[23]  R. Rico-Hesse,et al.  Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. , 1997, Virology.

[24]  M. Aye,et al.  Risk factors in dengue shock syndrome. , 1997, The American journal of tropical medicine and hygiene.

[25]  A. Rothman,et al.  Analysis of Murine CD8+ T-Cell Clones Specific for the Dengue Virus NS3 Protein: Flavivirus Cross-Reactivity and Influence of Infecting Serotype , 1999, Journal of Virology.

[26]  F. Ennis,et al.  Definition of the region on NS 3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive , HLA-DPw 2-restricted CD 4 M T cell clones , 1998 .

[27]  S. Lam,et al.  Dengue haemorrhagic fever , 1995 .

[28]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[29]  F. Ennis,et al.  A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities , 1995, The Journal of experimental medicine.

[30]  C. Parrish,et al.  Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to flaviviruses. , 1992, The Journal of general virology.

[31]  Y. S. Lin,et al.  Immunopathogenesis of dengue virus infection. , 2001, Journal of biomedical science.

[32]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Nisalak,et al.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.